Helixgate

Helixgate

BioPharma Dive – AI / Data

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

Published

on

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma Dive – AI / Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

Published

on

The treatment, tozorakimab, succeeded where other similar therapies failed and could help a broader group of COPD patients than Dupixent. 

Continue Reading

BioPharma Dive – AI / Data

Novartis targets Xolair successor in buyout of startup Excellergy

Published

on

Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine. 

Continue Reading

BioPharma Dive – AI / Data

Rocket gene therapy cleared by FDA for rare immune disorder

Published

on

Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since 2021 amid several setbacks.  

Continue Reading
Advertisement

Trending